1. Market Research
  2. > Hypoxic-Ischemic Encephalopathy – Pipeline Review, H1 2013

Hypoxic-Ischemic Encephalopathy – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 28 pages

Hypoxic-Ischemic Encephalopathy – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Hypoxic-Ischemic Encephalopathy - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hypoxic-Ischemic Encephalopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypoxic-Ischemic Encephalopathy. Hypoxic-Ischemic Encephalopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hypoxic-Ischemic Encephalopathy.
- A review of the Hypoxic-Ischemic Encephalopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypoxic-Ischemic Encephalopathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hypoxic-Ischemic Encephalopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypoxic-Ischemic Encephalopathy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Hypoxic-Ischemic Encephalopathy - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Hypoxic-Ischemic Encephalopathy Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Hypoxic-Ischemic Encephalopathy 6
Hypoxic-Ischemic Encephalopathy Therapeutics under Development by Companies 8
Hypoxic-Ischemic Encephalopathy Therapeutics under Investigation by Universities/Institutes 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Hypoxic-Ischemic Encephalopathy Therapeutics - Products under Development by Companies 13
Hypoxic-Ischemic Encephalopathy Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Hypoxic-Ischemic Encephalopathy Therapeutics Development 15
Chiesi Farmaceutici SpA 15
Hypoxic-Ischemic Encephalopathy - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
epoetin alfa - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Cerebrolysin - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
topiramate - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
darbepoetin alfa - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Caspase-2 Inhibitor - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Hypoxic-Ischemic Encephalopathy Therapeutics - Dormant Products 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28



List of Tables

Number of Products Under Development for Hypoxic-Ischemic Encephalopathy, H1 2013 6
Products under Development for Hypoxic-Ischemic Encephalopathy - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Number of Products under Investigation by Universities/Institutes, H1 2013 9
Comparative Analysis by Mid Clinical Stage Development, H1 2013 10
Comparative Analysis by Early Clinical Stage Development, H1 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 14
Chiesi Farmaceutici SpA, H1 2013 15
Assessment by Monotherapy Products, H1 2013 16
Assessment by Stage and Route of Administration, H1 2013 18
Assessment by Stage and Molecule Type, H1 2013 20
Hypoxic-Ischemic Encephalopathy Therapeutics - Dormant Products 26



List of Figures

Number of Products under Development for Hypoxic-Ischemic Encephalopathy, H1 2013 6
Products under Development for Hypoxic-Ischemic Encephalopathy - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Products under Investigation by Universities/Institutes, H1 2013 9
Mid Clinical Stage Products, H1 2013 10
Early Clinical Stage Products, H1 2013 11
Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 16
Assessment by Route of Administration, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 18
Assessment by Molecule Type, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.